Skip to main content

Table 1 Patient characteristics (n = 204)

From: Erratum to: A retrospective study to identify risk factors for somnolence and dizziness in patients treated with pregabalin

Age
 Median, year 61
 Range, year 18-92
Gender
 Male, n(%) 123 (60.3)
 Female , n(%) 81 (39.7)
Median CLcra, mL/min 88.7
NPb origin
 Cancer related NP, n(%) 55 (27.0)
 Chemotherapy related NP, n(%) 24 (11.7)
 Non-cancer related NP, n(%) 125 (61.3)
Regular strong opioid
 yes, n(%) 36 (17.6)
  -fentanyl, n 17
  -oxycodone, n 16
  -morphine, n 3
  Median dosec (range), mg/day 60 (15–300)
 no, n(%) 168 (82.4)
Initial dose of pregabalin
 150 mg/day, n(%) 124 (60.8)
 75 mg/day, n(%) 73 (35.8)
 50 mg/day, n(%) 3 (1.5)
 25 mg/day, n(%) 4 (1.9)
  1. aCLcr: creatinine clearance using the Cockcroft-Gault equation
  2. bNP: neuropathic pain
  3. cconverted to oral morphine